

CLAIM AMENDMENTS

Claims 1 through 11 (canceled)

1           12. (previously presented) A synergistic pharmaceutical  
2 composition for treating spasticity which consists essentially of  
3 as active ingredients:

4           (a) 40 to 60 parts by weight of tolperisone or eperisone;  
5 and

6           (b) 10 parts by weight of dextromethorphan, together with  
7 a pharmaceutically acceptable inert carrier.

1           13. (previously presented) The pharmaceutical composi-  
2 tion according to claim 12 wherein the active ingredients are 40 to  
3 60 parts by weight of tolperisone and 10 parts by weight of  
4 dextromethorphan.

1           14. (previously presented) The pharmaceutical composi-  
2 tion according to claim 13 wherein a unit of the composition  
3 contains 150 mg tolperisone and 30 mg dextromethorphan in admixture  
4 with a pharmaceutically acceptable inert carrier.

1           15. (previously presented) The pharmaceutical composi-  
2 tion according to claim 12 wherein the unit of the composition

3 includes a pharmaceutically acceptable inert carrier suitable for  
4 oral administration.

1 16. (previously presented) A method of treating and/or  
2 inhibiting spasticity which comprises the step of administering to  
3 a patient in need of said treatment, an anti-spasmodically effec-  
4 tive amount of the synergistic pharmaceutical composition defined  
5 in claim 12.

1 17. (previously presented) The method of treating and/or  
2 inhibiting spasticity defined in claim 16 wherein the pharmaceuti-  
3 cal composition is orally administered to the patient in need of  
4 said treatment.

1 18. (New) A synergistic anti-allodynic pharmaceutical  
2 composition for the treatment of chronic pain, which consists of:  
3 (a) 15 parts by weight of tolperisone; and  
4 (b) 3 parts by weight of dextromethorphan, together with  
5 a pharmaceutically acceptable inert carrier.

1 19. (New) The synergistic anti-allodynic pharmaceutical  
2 composition for the treatment of chronic pain defined in claim 18  
3 wherein the pharmaceutically acceptable inert carrier is suitable  
4 for oral administration.

1           20. (New) An anti-allodynic method of treating or  
2     inhibiting chronic pain, which comprises the step of administering  
3     to a patient in need of said treatment, an analgesically effective  
4     amount of the pharmaceutical composition defined in claim 18.

1           21. (New) An anti-allodynic method of treating or  
2     inhibiting chronic pain, which comprises the step of administering  
3     to a patient in need of said treatment, an analgesically effective  
4     amount of the pharmaceutical composition defined in claim 19.

1           22. (New) A synergistic pharmaceutical composition for  
2     treating spasticity and chronic pain, which consists of:  
3             (a) 5 to 20 parts by weight of tolperisone; and  
4             (b) 1 part by weight of dextromethorphan, together with a  
5     pharmaceutically acceptable inert carrier.

1           23. (New) The synergistic pharmaceutical composition for  
2     treating spasticity and chronic pain defined in claim 22, which  
3     consists of  
4             (a) 5 parts by weight of tolperisone; and  
5             (b) 1 part by weight of dextromethorphan, together with a  
6     pharmaceutically acceptable inert carrier.

1           24. (New) The synergistic pharmaceutical composition for  
2 treating spasticity and chronic pain defined in claim 22, which  
3 consists of

4           (a) 10 parts by weight of tolperisone; and

5           (b) 1 part by weight of dextromethorphan, together with a  
6 pharmaceutically acceptable inert carrier.

1           25. (New) The synergistic pharmaceutical composition for  
2 treating spasticity and chronic pain defined in claim 22, which  
3 consists of

4           (a) 20 parts by weight of tolperisone; and

5           (b) 1 part by weight of dextromethorphan, together with a  
6 pharmaceutically acceptable inert carrier.

1           26. (New) A method of treating spasticity or chronic  
2 pain, which comprises the step of administering to a patient in  
3 need of said treatment, an analgesically effective amount of the  
4 pharmaceutical composition defined in claim 22.

1           27. (New) A synergistic pharmaceutical composition for  
2 treating spasticity and chronic pain, which consists of:

3           (a) 25 parts by weight of tolperisone; and

4           (b) .25 to 1 part by weight of dextromethorphan, together  
5 with a pharmaceutically acceptable inert carrier.

1           28. (New) A method of treating spasticity or chronic  
2 pain, which comprises the step of administering to a patient in  
3 need of said treatment, an analgesically effective amount of the  
4 pharmaceutical composition defined in claim 27.

1           29. (New) A synergistic pharmaceutical composition for  
2 treating spasticity and chronic pain, which consists of:

3           (a) 20 parts by weight of eperisone; and

4           (b) .25 to 1 part by weight of dextromethorphan, together  
5 with a pharmaceutically acceptable inert carrier.

1           30. (new) A method of treating spasticity or chronic  
2 pain, which comprises the step of administering to a patient in  
3 need of said treatment, an analgesically effective amount of the  
4 pharmaceutical composition defined in claim 29.